Evolent Health, Inc (NYSE:EVH) – Research analysts at Oppenheimer Holdings dropped their FY2017 earnings estimates for Evolent Health in a report issued on Tuesday. Oppenheimer Holdings analyst M. Naidu now expects that the technology company will post earnings per share of ($0.63) for the year, down from their prior forecast of ($0.59). Oppenheimer Holdings also issued estimates for Evolent Health’s Q4 2017 earnings at ($0.09) EPS and Q1 2018 earnings at ($0.05) EPS.
Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Monday, August 7th. The technology company reported ($0.13) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The firm had revenue of $107.30 million during the quarter, compared to analyst estimates of $104.45 million. Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The business’s quarterly revenue was up 89.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.20) EPS. TRADEMARK VIOLATION NOTICE: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/2801443/fy2017-eps-estimates-for-evolent-health-inc-nyseevh-reduced-by-oppenheimer-holdings.html.
EVH has been the subject of several other reports. BidaskClub downgraded Evolent Health from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Robert W. Baird reaffirmed an “outperform” rating and set a $35.00 target price (up from $30.00) on shares of Evolent Health in a research note on Wednesday, June 14th. TheStreet raised Evolent Health from a “d” rating to a “c-” rating in a research note on Monday, May 22nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Evolent Health in a research note on Thursday, April 13th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $32.00 target price (up from $30.00) on shares of Evolent Health in a research note on Monday, June 19th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $29.90.
Shares of Evolent Health (NYSE:EVH) traded up 3.258% during midday trading on Friday, hitting $18.225. 668,783 shares of the stock were exchanged. The firm’s market cap is $1.20 billion. The firm’s 50-day moving average is $24.94 and its 200 day moving average is $22.68. Evolent Health has a 52-week low of $14.50 and a 52-week high of $27.50.
In other Evolent Health news, Director Cheryl Scott sold 5,477 shares of the company’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $23.51, for a total value of $128,764.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Seth Blackley sold 15,000 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $25.00, for a total value of $375,000.00. Following the completion of the sale, the president now owns 760,944 shares of the company’s stock, valued at $19,023,600. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,153,967 shares of company stock valued at $253,648,377. 8.79% of the stock is owned by corporate insiders.
A number of hedge funds have recently modified their holdings of EVH. BNP Paribas Arbitrage SA boosted its stake in shares of Evolent Health by 815.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after buying an additional 4,232 shares during the last quarter. US Bancorp DE boosted its stake in shares of Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after buying an additional 19 shares during the last quarter. Point72 Asia Hong Kong Ltd bought a new stake in shares of Evolent Health during the first quarter valued at about $126,000. Bank of Montreal Can boosted its stake in shares of Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock valued at $138,000 after buying an additional 6,077 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Evolent Health by 286.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,744 shares of the technology company’s stock valued at $150,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 73.16% of the company’s stock.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.